Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Nationwide real-world outcomes of POEMS syndrome: Long-term impact of ASCT, maintenance therapy, and relapse strategies in Japan

Emiko Sakaida, Shokichi Tsukamoto, Chikako Ohwada et al. Nov 03, 2025 pp. 5737-5737 10.1182/blood-2025-5737

Abstract Introduction POEMS syndrome is a rare plasma cell disorder classified as a myeloma-related disease. It presents complex multisystem...

Single-cell multi-omics uncovers transposable element regulation in hematopoietic stem and progenitor cells during aging

Logan Rivera, Tingting Hong, Yun Huang Nov 03, 2025 pp. 3161-3161 10.1182/blood-2025-3161

Abstract Clonal hematopoiesis (CH), the clonal expansion of mutant hematopoietic stem and progenitor cells (HSPCs), is highly prevalent in a...

National practice patterns and preferences in the use of fixed-duration vs. treat-to-progression therapies for CLL

Tisheeka Graham, Tariqa Ackbarali, Catherine Coombs et al. Nov 03, 2025 pp. 8095-8095 10.1182/blood-2025-8095

Abstract BACKGROUND: Targeted therapies are the standard approach within the treatment landscape for chronic lymphocytic leukemia (CLL), yet...

Identification of stage-specific regulators for neutrophil granule biogenesis

Wimeth Dissanayake, Stamatina Aravani, Emma Roberts et al. Nov 03, 2025 pp. 4761-4761 10.1182/blood-2025-4761

Abstract Neutrophil granules are membrane-bound compartments crucial for host defense, mediating these leukocyte's potent antimicrobial, inf...

Clone wars: Evidence of clonal stability in a longitudinal prospective cohort of cancer survivors with serial NGS analysis

Anmol Goyal, Akriti Jain, Salendra Singh et al. Nov 03, 2025 pp. 6712-6712 10.1182/blood-2025-6712

Abstract Introduction: Hematopoietic stem and progenitor cells with preleukemic mutations (mutns), collectively termed clonal hematopoiesis...

High risk of bleeding following CAR T-cell therapy: Insights from the dutch “Follow that CAR!” registry

Amica Ko, Pim Mutsaers, Lukas Van Kleij et al. Nov 03, 2025 pp. 315-315 10.1182/blood-2025-315

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment and outcomes for patients with relapsed/ref...

Chemotherapy selects for myeloid subclones in multiple subtypes of B-cell acute lymphoblastic leukemia

Fatemeh Alikarami, Rushabh Mehta, Changya Chen et al. Nov 03, 2025 pp. 35-35 10.1182/blood-2025-35

Abstract Lineage infidelity, manifested as either lineage drift or lineage switch, has emerged as a mechanism of resistance to B-cell–target...

Burden and trends of sickle cell disease in the United States: Insights from the global burden of disease study 2021

Sameer Kumar Majety, Megha Sasidhar Handral, Rithish Nimmagadda et al. Nov 03, 2025 pp. 6227-6227 10.1182/blood-2025-6227

Abstract Background: Sickle Cell Disease (SCD) remains a major public health concern in the United States, with substantial geographic and d...

The exercise-induced myokine irisin acts as an endogenous anti-thrombotic agent by modulating multiple target cells

Martha Sim, Daniel Gao, Jennie Le et al. Nov 03, 2025 pp. 425-425 10.1182/blood-2025-425

Abstract Background and Objective Exercise is known to reduce thrombotic risk and systemic inflammation, but the underlying mechanisms are n...

Low-dose nivolumab combined with AVD chemotherapy (Nivo40-AVD) for advanced stage classic Hodgkin lymphoma

Mobil Akhmedov, Pervin Zeynalova, Mariya Vernyuk et al. Nov 03, 2025 pp. 1855-1855 10.1182/blood-2025-1855

Abstract Recently published SWOG S1826 trial demonstrated high efficacy and low toxicity of first-line nivolumab combined with adriamycin, v...

Cell cycle-related genetic variants are frequently acquired at relapse of acute lymphoblastic leukemia and predict worse post-relapse prognosis

Jinho Lee, Namsoo Kim, Yu Jeong Choi et al. Nov 03, 2025 pp. 3323-3323 10.1182/blood-2025-3323

Abstract Introduction:While the genetic landscape of acute lymphoblastic leukemia (ALL) at diagnosis has been deeply elucidated, its genetic...

Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study

Hu Mao Gui, Jing Ming, Jing Wang et al. Nov 03, 2025 pp. 3597-3597 10.1182/blood-2025-3597

Abstract Background: Marginal zone lymphoma (MZL) is an indolent B-cell lymphoma with distinct subtypes, including mucosa-associated lymphoid...

Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability

Umar Iqbal, Onyee Chan, Rory Shallis et al. Nov 03, 2025 pp. 3448-3448 10.1182/blood-2025-3448

Abstract Background: Revumenib was approved by the US Food and Drug Administration on 11/15/2024 as the first menin inhibitor for treatment o...

FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China

Yongzhi Zheng, Jian Li, Huiping Li et al. Nov 03, 2025 pp. 5152-5152 10.1182/blood-2025-5152

Abstract Background: The FLAG-IDA (fludarabine, high-dose cytarabine, granulocyte colony-stimulating factor, and idarubicin) regimen is rare...

Lentiviral vector transduced autologous CD34+ cells with FVIII transgene for gene therapy of Hemophilia A with history of inhibitors

Aby Abraham, Fouzia N., Gurbind Singh et al. Nov 03, 2025 pp. 6087-6087 10.1182/blood-2025-6087

Abstract There has been no report demonstrating measurable plasma FVIII after gene therapy for hemophilia A with history of inhibitors. We h...

Spatial immunophenotyping of PD1 and PDL1 in tumor cells and microenvironment of nodal follicular T helper cell lymphoma

Farnoush Moen, Ananya Datta Mitra, Shafagh Parsazad et al. Nov 03, 2025 pp. 7084-7084 10.1182/blood-2025-7084

Abstract Background: Nodal T follicular helper cell lymphomas (nTFHLs) represent a group of mature T cell lymphomas with heterogenous microe...

Selinexor alone and in combination with JAK inhibitors suppresses pro-inflammatory cytokine secretion from primary myelofibrosis cells ex vivo

Trinayan Kashyap, Christopher Walker, Andrea Ellero et al. Nov 03, 2025 pp. 5537-5537 10.1182/blood-2025-5537

Abstract Introduction: Selinexor (SEL) is an oral selective inhibitor of the nuclear export protein exportin 1 (XPO1). In combination with r...

Real-world experience with hematopoietic stem cell transplantation in acute leukemias: Clinical landscape and impact of early cyclosporine a exposure on post-transplant complications and outcomes

Oscar Jaime Moreno-García, Amaya Llorente-Chávez, Kenya Esmeralda Mendoza-Salguero et al. Nov 03, 2025 pp. 7749-7749 10.1182/blood-2025-7749

Abstract Introduction Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a potentially curative therapy for high-risk ac...

Single cell multiomics dissection of In Vivo immune modulation and reconstitution induced by bruton's kinase inhibitors in CLL patients

Anna Gurevich Shapiro, Eyal David, Reut Sharet-Eshed et al. Nov 03, 2025 pp. 2105-2105 10.1182/blood-2025-2105

Abstract Background: Bruton's Tyrosine Kinase inhibitors (BTKi) have transformed the treatment landscape of Chronic Lymphocytic Leukemia (CL...

Non-hematotoxic Tim-3/CD70 dual-targeting CAR T cells promote potent anti-leukemia activity against acute myeloid leukemia

Sophia Chen, Adhithi Rajagopalan, Katerina Su et al. Nov 03, 2025 pp. 2345-2345 10.1182/blood-2025-2345

Abstract BACKGROUND Chimeric antigen receptor (CAR) T cell therapy for acute myeloid leukemia (AML) faces major challenges due to the lack o...

Baseline immune and proteomic profiling predicts response and resistance to CD19 CAR T-cell therapy in B-cell non-Hodgkin lymphoma: Insights from a decentralized manufacturing clinical trial

Arun Arunachalam, Jessica Kerr, Jane Reese et al. Nov 03, 2025 pp. 567-567 10.1182/blood-2025-567

Abstract IntroductionCD19-directed CAR T-cell therapy has transformed the therapeutic landscape for relapsed/refractory B-cell non-Hodgkin l...

Years of life lost to multiple myeloma remains high: A targeted literature review

Roberto Mina, Amruta Radhakrishnan, Anupama Vasudevan et al. Nov 03, 2025 pp. 2804-2804 10.1182/blood-2025-2804

Abstract Introduction: Despite treatment advances, multiple myeloma (MM) remains an incurable disease that may eventually become therapy res...

Safety and efficacy of transposon, BAFF-ligand directed chimeric antigen receptor T cells (LMY-920) with pre-apheresis obinutuzumab for patients with Relapsed/Refractory chronic lymphocytic leukemia and small lymphocytic lymphoma

Paolo Caimi, Leland Metheny, Lapo Alinari et al. Nov 03, 2025 pp. 4177-4177 10.1182/blood-2025-4177

Abstract Background and Significance: Despite major therapeutic advances including BTK and BCL2 inhibitors, patients with relapsed/refractor...

Varnimcabtagene autoleucel in relapsed / refractory B-cell malignancies: Manufacturing experience from India

Anil Kamat, Varun Lahoti, Parag Deshpande et al. Nov 03, 2025 pp. 2409-2409 10.1182/blood-2025-2409

Abstract Introduction: Varnimcabtagene autoleucel (varnim-cel), a CD19 antigen-directed chimeric antigen receptor (CAR) T cell therapy with...

Duffy null phenotyping reduces unnecessary workup in asymptomatic neutropenia: A quality initiative in a correctional hematology clinic

Ashish Sharma, Harendra Kumar, Angad Tiwari et al. Nov 03, 2025 pp. 6545-6545 10.1182/blood-2025-6545

Abstract Background: Referrals for neutropenia are common in hematology clinics serving the Department of Corrections (DOC) population. Many...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page